Lantus Assistance Programs & Grants

Status: Accepting applications on August 26, 2026. Lantus (insulin glargine) is named on the program's published medications-available list, along with Toujeo and an unbranded Insulin Glargine U-300.

Sanofi's patient assistance program covers Lantus and publishes a clear income test. What it does not publish is how it treats Medicare — so this page records the criteria that exist and tells you to ask about the one that does not.

If you have Medicare: This is an honest gap rather than an exclusion. Sanofi Patient Connection publishes three eligibility criteria — US residency, an annual household income at or below 400% of the federal poverty level, and, for commercially insured patients, having "no insurance coverage or access to the prescribed product" — and none of them mentions Medicare. The program describes itself as being for uninsured or functionally uninsured patients, which is language that could include a Medicare beneficiary whose plan does not cover the product, but Sanofi does not say so. Call 1-888-847-4877 and ask directly whether Medicare Part D enrollees may apply and what "access to the prescribed product" means for someone whose plan covers a different glargine.

What it can cover: Sanofi medications, including Lantus, for approved patients who meet the income and insurance criteria.

Status: Active on August 26, 2026 at $35 per 30-day supply. The condition attached to that price is that you must fill all of your Sanofi insulin prescriptions at the same time, together each month.

A genuine $35 cash price for Lantus, available to Medicare beneficiaries willing to buy outside their drug plan. Whether it is a good idea depends entirely on what else you take, because the spending does not count toward your Part D cap.

If you have Medicare: This is the most consequential paragraph on the page, so read it slowly. The offer is "only valid for those who are uninsured or those who are insured by a prescription plan but are not using such insurance and will be paying the full retail price for the medication." A Medicare beneficiary therefore CAN use it — by stepping outside Part D and paying cash. But Sanofi's terms continue: "You may not submit claims for reimbursement to any third-party payor, including any government healthcare plan (e.g., Medicare, Medicaid, DOD, VA, TRICARE)... You may not seek to have your out-of-pocket costs or the full retail price of the Sanofi Insulin count toward your deductible, true-out-of-pocket (TrOOP), maximum out-of-pocket (MOOP), or any other out-of-pocket caps associated with any insurance coverage." In plain terms: every dollar you spend this way makes no progress toward the $2,100 Part D out-of-pocket cap. If Lantus is the only expensive drug you take, that may not matter. If you take other costly medications and expect to reach the cap, buying insulin outside your plan can push the date you reach it later — or out of reach entirely — and cost you more across the year than it saves each month.

What it can cover: Lantus, and other Sanofi insulins filled at the same time, at $35 per 30-day supply. Not insurance.

Status: Active for commercially insured patients on August 26, 2026: no more than $35 for a 30-day supply, valid up to 10 packs per fill.

A commercial copay card, and the one of Sanofi's two $35 offers that Medicare beneficiaries genuinely cannot use. Recorded here so the difference between the two is clear before you call.

If you have Medicare: Sanofi's terms are explicit: "This offer is not valid for prescriptions covered by or submitted for reimbursement, in whole or in part, under Medicare, Medicaid, VA, DOD, TRICARE, similar federal or state programs, including any state pharmaceutical programs." Note the distinction from the Valyou program above, which is not a copay card and which Medicare beneficiaries can use by paying cash. The two are easy to confuse because both quote $35.

What it can cover: Part of the commercial copay for Sanofi insulins. Not applicable to Medicare cost-sharing.

Status: Both funds were closed to new applicants on August 26, 2026, each with a $1,500 guaranteed and $2,000 maximum award. TotalAssist has no waitlist, so the notification sign-up is what gets you in.

Lantus and Lantus Solostar are both named on the Type 2 diabetes approved-medication list, alongside Basaglar, Semglee, Rezvoglar and unbranded insulin glargine — so a switch between glargine products would not cost you fund eligibility. Note that these are type 2 funds: no foundation on this list runs a type 1 diabetes fund.

If you have Medicare: These funds require government-insured coverage — Medicare, Medicaid or TRICARE — that covers your qualifying expenses. Medicare beneficiaries are eligible when a fund is open. One caution specific to insulin: if you buy Lantus with cash through the Valyou program, you are not using your insurance for it, which may affect what the fund can pay toward.

What it can cover: When open: $1,500 guaranteed award and up to $2,000 maximum for medication copays, coinsurance, deductibles and health-insurance premiums. One grant per condition.

Status: Closed on August 26, 2026. HealthWell runs no Type 1 Diabetes fund and no insulin-specific fund, so there is no alternative fund for someone taking Lantus for type 1 diabetes.

One applicable fund, closed. Worth flagging plainly: if you take Lantus for type 1 diabetes, none of the three foundations on this page runs a fund you could apply to, which makes the manufacturer routes and the $35 Medicare insulin cost-sharing the whole picture.

If you have Medicare: HealthWell accepts Medicare beneficiaries for the diseases it covers. Its Type 2 Diabetes fund was closed when we checked.

What it can cover: When open: copays, coinsurance, deductibles and health-insurance premiums for type 2 diabetes.